Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

David Sharon, Fengjiao Dunbar, Paul Jung, Xifeng Wang, Xiaotong Li, Christine Mantis, Orlando F. Bueno, Cyrille Touzeau, Philippe Moreau, Simon J Harrison, Luciano J. Costa, Jonathan L. Kaufman, Nizar J. Bahlis, Shaji K Kumar, Jeremy A. Ross, P.K. Epling-Burnette

Blood (2022) 140 (Supplement 1): 4242–4244.

https://doi.org/10.1182/blood-2022-160195

Published: 2022

Journal Articles

Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a

Blood (2019) 134 (Supplement_1): 4220.

https://doi.org/10.1182/blood-2019-128165

Published: 2019

Journal Articles

EZH2 Protein Expression Is Decreased in MDS and MDS/MPN and Correlated with EZH2 Mutation Status, Chromosomal 7 Abnormalities and Clinical Outcome

Kathy L Mcgraw, PhD, Johnny Nguyen, Najla Alali, MS, Jinming Song, MD PhD, David Sallman, MD, Eric Padron, MD, Jeffrey E. Lancet, MD, Daihui Qin, P.K. Epling-Burnette, PhD, Lynn C. Moscinski, MD, Rami S. Komrokji, MD, Alan F List, MD, Ling Zhang, MD

Blood (2016) 128 (22): 4305.

https://doi.org/10.1182/blood.V128.22.4305.4305

Published: 2016

Journal Articles

Molecular Characterization of SRSF2 Mutation Identifies a Clinically Relevant Lncrna (MALAT1) in Chronic Myelomonocytic Leukemia (CMML)

Maria E. Balasis, Jane Merelvede, Sateesh Kunigal, Xiaoyi Ren, Yan Ma, Qing Zhang, PhD, Jeff Painter, Nathalie M. Droin, PhD, Joseph Johnson, Sean Yoder, M.S, Rami S. Komrokji, MD, Ling Zhang, MD, Sheng Wei, MD, Torsten Haferlach, Robert MacLeod, PhD, Alan F. List, MD, Eric Solary, MD Prof, P.K. Epling-Burnette, PhD, Eric Padron, MD

Blood (2015) 126 (23): 1641.

https://doi.org/10.1182/blood.V126.23.1641.1641

Published: 2015

Journal Articles

A Close Association of History of Autoimmunity with Chronic Myelomonocytic Leukemia (CMML) in Contrast to Chronic Myelogenous Leukemia (CML)

Deniz Peker, MD, Eric Padron, MD, Pedro Horna, MD, John M. Bennett, MD, Xiaohui Zhang, MD, P.K. Epling-Burnette, PharmD, PhD, Jeffrey E Lancet, MD, Javier Pinilla, Lynn Moscinski, MD, Alan F. List, MD, Rami S. Komrokji, MD, Ling Zhang, MD

Blood (2012) 120 (21): 1712.

https://doi.org/10.1182/blood.V120.21.1712.1712

Published: 2012

Journal Articles

Preclinical Characterization of KB003, a Novel Humaneered™ Monoclonal Anti-GM-CSF Antibody, Demonstrates That the GM-CSF Signaling Axis Is a Therapeutic Target in Chronic Myelomonocytic Leukemia (CMML)

Eric Padron, MD, Jeffrey S Painter, BS, Adam W Mailloux, PhD, Kathy L. McGraw, Jessica M. McDaniel, BS, Christopher Bebbington, DPhil., Mark Baer, PhD, Geoffrey Yarranton, PhD, Jeffrey E Lancet, MD, Rami S. Komrokji, MD, Alan F. List, MD, P.K. Epling-Burnette, PharmD, PhD

Blood (2012) 120 (21): 3793.

https://doi.org/10.1182/blood.V120.21.3793.3793

Published: 2012

Journal Articles

Hypomethylating Agents Improve Overall Survival in Higher Risk Chronic Myelomonocytic Leukemia (CMML)

Eric Padron, MD, Najla H Al Ali, Deniz Peker, MD, Jeffrey E Lancet, MD, P.K. Epling-Burnette, PharmD, PhD, Ling Zhang, MD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2012) 120 (21): 3838.

https://doi.org/10.1182/blood.V120.21.3838.3838

Published: 2012

Journal Articles

Association of MDM2 G ene Polymorphisms SNP285 and 309 with Myelodysplastic Syndromes (MDS) Susceptibility and Outcome.

Blood (2012) 120 (21): 2823.

https://doi.org/10.1182/blood.V120.21.2823.2823

Published: 2012

Journal Articles

Enhanced Immunological Responses Following K562/GM-CSF/CD40L Vaccine Plus Lenalidomide in High-Risk Myelodysplastic Syndrome

John Powers, B.S., Eric Padron, MD, Jason Dubovsky, Ph.D, Emmanuel Berchmans, B.S., Tyler Farnum, Fanqi Bai, MD, Eva Sahakian, Ph.D, Jamil Ahmed, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Alan F. List, MD, Douglas G McNeel, MD, Sophie Dessureault, MD, Scott Antonia, MD, Eduardo M. Sotomayor, P.K. Epling-Burnette, PharmD, PhD, Javier Pinilla-Ibarz, MD, PhD

Blood (2011) 118 (21): 1725.

https://doi.org/10.1182/blood.V118.21.1725.1725

Published: 2011

Journal Articles

A Switch in Regulatory T-Cell Memory Phenotype Is Associated with Poor Survival in Lower Risk Myleodysplastic Syndrome Patients

Adam W Mailloux, PhD, Chiharu Sugimori, Rami S. Komrokji, MD, Jaroslaw P. Maciejewski, MD, PhD, Ronald Paquette, MD, PhD, Thomas P. Loughran, Jr., MD, Alan F. List, MD, P.K. Epling-Burnette, PharmD, PhD

Blood (2011) 118 (21): 1703.

https://doi.org/10.1182/blood.V118.21.1703.1703

Published: 2011

Journal Articles

Cytopenias in Large Granular Lymphocyte Leukemia Are Mediated by Pro-Fibrotic Mesenchymal Stem Cells in the Bone Marrow Niche with Functional Restoration by FGFb

Adam W Mailloux, PhD, Ling Zhang, MD, Lili Yang, PhD, Cody Wei, Lubomir Sokol, MD, PhD, Lynn Moscinski, MD, John M. Bennett, MD, Thomas P. Loughran, Jr., MD, P.K. Epling-Burnette, PharmD, PhD

Blood (2011) 118 (21): 932.

https://doi.org/10.1182/blood.V118.21.932.932

Published: 2011

Journal Articles

CD8+ CD28 null T Cell Expansion Impairs Lenalidomide Immunomodulatory Function in Myelodysplastic Syndrome

Jessica M. McDaniel, BS, JianXiang Zou, MD, Alan F. List, MD, P.K. Epling-Burnette, PharmD, PhD

Blood (2011) 118 (21): 1117.

https://doi.org/10.1182/blood.V118.21.1117.1117

Published: 2011

Journal Articles

Microenvironment Induced Myelodysplastic Syndrome (MDS) in S100A9 Transgenic Mice Caused by Myeloid-Derived Suppressor Cells (MDSC)

Sheng Wei, MD, Xianghong Chen, Junmin Zhou, Ph.D, Ling Zhang, MD, Nicole R. Fortenbery, Sarah S Rasche, Ph.D, Kathy McGraw, Erika A. Eksioglu, Ph.D, P.K. Epling-Burnette, PhD, Julie Y. Djeu, Ph.D, Dmitry I. Gabrilovich, Ph.D, Alan F. List, MD

Blood (2011) 118 (21): 788.

https://doi.org/10.1182/blood.V118.21.788.788

Published: 2011

Journal Articles

Autoproliferation Contributes to Clonal Expansion and Changes In Cellular Topography In T Cell Large Granular Lymphocyte (LGL) Leukemia

JianXiang Zou, MD, Jeffrey S Painter, BS, Fanqi Bai, MD, Lubomir Sokol, MD, PhD, Thomas P. Loughran, Jr., MD, P.K. Epling-Burnette, PharmD, PhD

Blood (2010) 116 (21): 1373.

https://doi.org/10.1182/blood.V116.21.1373.1373

Published: 2010

Journal Articles

HTLV-1 Epitope (BA21) Reactivity in Rare Bone Marrow Failure Diseases

Susan Bell Nyland, Ph.D., Daniel J. Krissinger, Michael Clemente, M.S., Rosalyn B. Irby, Ph.D., Kendall Thomas Baab, Nancy Ruth Jarbadan, Lubomir Sokol, M.D., Ph.D., Eric Schaefer, M.S., Jason Liao, Ph.D., David Cuthbertson, M.S., P.K. Epling-Burnette, PharmD, PhD, Ronald Paquette, MD, PhD, Jaroslaw P. Maciejewski, MD, PhD, FACP, Thomas P. Loughran, Jr., M.D.

Blood (2010) 116 (21): 1724.

https://doi.org/10.1182/blood.V116.21.1724.1724

Published: 2010

Journal Articles

Phase 2 Multicenter Trial of Rabbit Anti-Thymocyte Serotherapy In Myelodysplastic Syndrome: Rate of Hematological Improvement Associated with Pre-Treatment Disease Duration

P.K. Epling-Burnette, PharmD, PhD, Rami S. Komrokji, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Mikkael A. Sekeres, MD, MS, Ronald Paquette, MD, Sheng Wei, MD, Jeffrey S Painter, BS, Fanqi Bai, MD, William J Fulp, Jennifer Paleveda-Pena, Dung-Tsa Chen, PhD, Alan F. List, MD

Blood (2010) 116 (21): 602.

https://doi.org/10.1182/blood.V116.21.602.602

Published: 2010

Journal Articles

Predisposition to Myelodysplastic Syndrome with Deletion 5q Is Associated with TP53 Codon 72 Genotype

Blood (2010) 116 (21): 612.

https://doi.org/10.1182/blood.V116.21.612.612

Published: 2010

Journal Articles

Hypoalbuminemia Is An Independent Prognostic Factor In Myelodysplastic Syndromes

Maria Corrales-Yepez, MD, Mohamed A. Kharfan-Dabaja, MD, Jeffrey Lancet, MD, Alan F. List, MD, Eric Padron, MD, Dana Rollison, PhD, P.K. Epling-Burnette, PharmD, PhD, Ling Zhang, MD, Teressa Field, MD, Javier Pinilla-Ibarz, MD, Rami S. Komrokji, MD

Blood (2010) 116 (21): 4001.

https://doi.org/10.1182/blood.V116.21.4001.4001

Published: 2010

Journal Articles

A Phase I Pilot Study of Bystander Vaccine and Lenalidomide Immune Augmentation In Patients with Myelodysplastic Syndrome (MDS)

Eric Padron, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Alan F. List, MD, Sophie Dessureault, Scott Antonia, Jamil Ahmed, Shiddhi Patel, John Powers, Fanqi Bai, Eduardo M. Sotomayor, MD, P.K. Epling-Burnette, PharmD, PhD, Javier Pinilla-Ibarz, MD

Blood (2010) 116 (21): 2925.

https://doi.org/10.1182/blood.V116.21.2925.2925

Published: 2010

Journal Articles

Deletions of Xp22.2 Including PIG-A Locus Lead to Paroxysmal Nocturnal Hemoglobinuria.

Christine L. O'Keefe, Chiharu Sugimori, Manuel Afable, Michael Clemente, Kenneth Shain, David Araten, Alan F. List, P.K. Epling-Burnette, Jaroslaw Maciejewski

Blood (2010) 116 (21): 1158.

https://doi.org/10.1182/blood.V116.21.1158.1158

Published: 2010

NARROW

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a

EZH2 Protein Expression Is Decreased in MDS and MDS/MPN and Correlated with EZH2 Mutation Status, Chromosomal 7 Abnormalities and Clinical Outcome

Molecular Characterization of SRSF2 Mutation Identifies a Clinically Relevant Lncrna (MALAT1) in Chronic Myelomonocytic Leukemia (CMML)

A Close Association of History of Autoimmunity with Chronic Myelomonocytic Leukemia (CMML) in Contrast to Chronic Myelogenous Leukemia (CML)

Preclinical Characterization of KB003, a Novel Humaneered™ Monoclonal Anti-GM-CSF Antibody, Demonstrates That the GM-CSF Signaling Axis Is a Therapeutic Target in Chronic Myelomonocytic Leukemia (CMML)

Hypomethylating Agents Improve Overall Survival in Higher Risk Chronic Myelomonocytic Leukemia (CMML)

Association of MDM2 G ene Polymorphisms SNP285 and 309 with Myelodysplastic Syndromes (MDS) Susceptibility and Outcome.

Enhanced Immunological Responses Following K562/GM-CSF/CD40L Vaccine Plus Lenalidomide in High-Risk Myelodysplastic Syndrome

A Switch in Regulatory T-Cell Memory Phenotype Is Associated with Poor Survival in Lower Risk Myleodysplastic Syndrome Patients

Cytopenias in Large Granular Lymphocyte Leukemia Are Mediated by Pro-Fibrotic Mesenchymal Stem Cells in the Bone Marrow Niche with Functional Restoration by FGFb

CD8+ CD28 null T Cell Expansion Impairs Lenalidomide Immunomodulatory Function in Myelodysplastic Syndrome

Microenvironment Induced Myelodysplastic Syndrome (MDS) in S100A9 Transgenic Mice Caused by Myeloid-Derived Suppressor Cells (MDSC)

Autoproliferation Contributes to Clonal Expansion and Changes In Cellular Topography In T Cell Large Granular Lymphocyte (LGL) Leukemia

HTLV-1 Epitope (BA21) Reactivity in Rare Bone Marrow Failure Diseases

Phase 2 Multicenter Trial of Rabbit Anti-Thymocyte Serotherapy In Myelodysplastic Syndrome: Rate of Hematological Improvement Associated with Pre-Treatment Disease Duration

Predisposition to Myelodysplastic Syndrome with Deletion 5q Is Associated with TP53 Codon 72 Genotype

Hypoalbuminemia Is An Independent Prognostic Factor In Myelodysplastic Syndromes

A Phase I Pilot Study of Bystander Vaccine and Lenalidomide Immune Augmentation In Patients with Myelodysplastic Syndrome (MDS)

Deletions of Xp22.2 Including PIG-A Locus Lead to Paroxysmal Nocturnal Hemoglobinuria.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only